Practical Management of Secondary Hyperparathyroidism:
From Basic Science to Clinical Medicine

ASN 2002 Offical Evening Symposium, November, 2002
Opening Remarks
Eduardo Slatopolsky, MD.
PTH Receptors in Chronic Renal Failure
Harald Jueppner, MD.
Efficacy of Paricalcitol in the Prevention and Treatment of Bone Disease in Experimental Renal Failure
Eduardo Slatopolsky, MD.
Update in the Assessment and Therapy of Secondary Hyperparathyroidism from Chronic Kidney Failure to ESRD
Kevin Martin, MD.

The educational objectives are:
1. Pathophysiology: Attendees should gain useful insight into the mechanisms underlying the causes and management of secondary hyperparathyroidism.
2. Clinical Presentations: Key clinical and diagnostic aspects of secondary hyperparathyroidism will be reviewed and updated.
3. Therapy: The understanding of the basis and the appreciation of the clinical appearance of secondary hyperparathyroidism will be translated into discussion of its therapy.
Harald Jueppner, MD
Massachusettes General Hospital
Pediatrics - MGH
Endocrine Unit
Boston, MA.

Eduardo Slatopolsky, MD
Washington University School of Medicine
Renal Division
St. Louis, MO.

Kevin J. Martin, MBBCh, FACP
St. Louis University Medical Center
Division of Nephrology
St. Louis, MO.

This group of talks is is accredited for up to 1.5 CME credit hours by the American Society of Nephrology. The CME post-test must be completed along with an evaluation form for 1.5 hour of CME credit.

Date of Web Release: June 1, 2003
CME Credit Eligible Through: May 1, 2004
CME Credit Hours/Completion Time: 1.5 h
Target Audiences: For CME accredited talks: Nephrology Board and Recertification candidates practicing nephrologists and internists
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the abstracts linked to post-test answer feedback material.

Chronic kidney disease affects 30-40 million Americans, of whom several thousand require renal replacement therapy. These selected lectures are chosen by the HDCN editor and ASN Postgraduate Medical Director to reflect those areas of practice of greatest interest to the clinician, and areas where recent progress has occurred. The web extension of these ASN lectures will allow nephrologists and other physicians who were unable to attend the live sessions to gain similar benefit from these presentations.

The American Society of Nephrology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Nephrology designates this educational activity for category 1.5 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

This official ASN symposium was sponsored by a restricted educational grant from Abbott Laboratories.

American Society of Nephrology, the Renal Education Association, as well as HDCN have conflict of interest policies that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Dr. Jueppner: discloses no apparent conflicts of pertaining to the material discussed in this talk.
Dr. Martin: Has grants, research support, or consultantships from: Abbott and Amgen. He is also a scientific advisor for Abbott and Amgen.
Dr. Slatopolsky: Has grants, research support or honorariam from Geltex, Chugai, Abbott or Genzyme. He is a clinical investigator for Genzyme and Chugai.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The American Society of Nephrology, the Renal Education Association, and HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete this educational activity, the user will need Windows or Macintosh operating software, a connection to the internet with a 28.8 kbps MODEM or better. The computer should have an audio card with speakers. An audio player, either the Windows Media Player from Microsoft or the Real Player from Real Media ( is required and either can be downloaded for free per instructions on the individual lecture pages. Acrobat Reader is required to print the CME or CE certificate, and this can be download free from

For any questions concerning this activity please send an email to or call HDCN at 630-325-3276.

This educational activity is supported by an educational grant from Abbott Laboratories
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.
This educational activity is based on an ASN evening symposium which was
planned by the ASN scientific program committee.